10.1523/ENEURO.0443-18.2019 [DOI] [PMC free article] [PubMed] [Google Scholar] Bouhlal, S
NCT04255433) is expected to provide definitive answers on the impact of tirzepatide on cardiovascular disease compared with dulaglutide, a long-acting GLP-1 RA that has been shown to be cardioprotective in individuals with type 2 diabetes at increased cardiovascular risk [31]
This can occur if you have inflammation of your stomach lining or disorders of the small intestine, such as Crohn's disease
CONCLUSIONS AND RELEVANCE This cohort study, including mostly patients with type 2 diabetes, does not show an association between use of GLP-1 receptor agonists and an increased risk of suicide death, self-harm, or incident depression and anxiety-related disorders
In cases of moderate to extreme skin concerns, you might need a broader treatment plan
Across cohorts, 48 weeks of retatrutide reduced liver fat by 50% or greater in 43-100% of participants and 70% or greater in 22-86%